CALCIUM POLYCARBOPHIL
(pol-ee-kar'boe-fil)
FiberCon, Mitrolan
Classifications: gastrointestinal agent; bulk laxative; antidiarrheal
Prototype: Psyllium hydrophilic muciloid
Pregnancy Category: C

Availability

500 mg, 625 mg, tablets

Actions

Hydrophilic, bulk-producing laxative that restores normal moisture level and bulk content of intestinal tract. In constipation, retains free water in intestinal lumen, thereby indirectly opposing dehydrating forces of the bowel; in diarrhea, when intestinal mucosa is incapable of absorbing fluid, drug absorbs fecal fluid to form a gel. In both conditions, peristalsis is encouraged and a well-formed stool is produced.

Therapeutic Effects

Relieves constipation or diarrhea associated with bowel disorders and acute nonspecific diarrhea.

Uses

Constipation or diarrhea associated with diverticulitis or irritable bowel syndrome; acute nonspecific diarrhea.

Contraindications

GI obstruction; children <6 y.

Cautious Use

Pregnancy (category C); lactation.

Route & Dosage

Constipation or Diarrhea
Adult: PO 1 g q.i.d. as needed (max: 6 g/24 h)
Child: PO 6–12 y, 500 mg 1–3 times/d (max: 3 g/24 h); <6 y, 500 mg 1–2 times/d (max: 1.5 g/24 h)

Administration

Oral

Adverse Effects (1%)

GI: Flatulence, abdominal fullness, intestinal obstruction; laxative dependence (long-term use).

Pharmacokinetics

Absorption: Calcium polycarbophil is not absorbed from the intestine. Bowel movement usually occurs within 12–72 h. Elimination: Excreted in feces.

Nursing Implications

Assessment & Drug Effects

Patient & Family Education


Common adverse effects in italic, life-threatening effects underlined; generic names in bold; classifications in SMALL CAPS; Canadian drug name; Prototype drug